Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
Stopped early · Phase 3 · Has a placebo group
Conditions studied: Relapsing-remitting Multiple Sclerosis
In brief
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with RMS.
Key facts
- Study ID
- NCT04032158
- Run by
- EMD Serono Research & Development Institute, Inc.
- People needed
- 3
- Starts
- 2019-08-26
- Expected to finish
- 2020-04-16
- Last updated by the study team
- 2021-08-05
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Please Contact U.S. Medical Information — Rockland, Massachusetts, United States
- Please Contact the Communication Center — Darmstadt, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.